ATE311464T1 - Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen - Google Patents

Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen

Info

Publication number
ATE311464T1
ATE311464T1 AT01956747T AT01956747T ATE311464T1 AT E311464 T1 ATE311464 T1 AT E311464T1 AT 01956747 T AT01956747 T AT 01956747T AT 01956747 T AT01956747 T AT 01956747T AT E311464 T1 ATE311464 T1 AT E311464T1
Authority
AT
Austria
Prior art keywords
cell
therapeutic
activated receptors
diagnostic uses
targeting
Prior art date
Application number
AT01956747T
Other languages
English (en)
Inventor
Ofer Mandelboim
Angel Porgador
Original Assignee
Yissum Res Dev Co
Univ Ben Gurion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Univ Ben Gurion filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE311464T1 publication Critical patent/ATE311464T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01956747T 2000-07-20 2001-07-19 Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen ATE311464T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL13741900A IL137419A0 (en) 2000-07-20 2000-07-20 Nk cells activating receptors and their therapeutic and diagnostic uses
PCT/IL2001/000664 WO2002008287A2 (en) 2000-07-20 2001-07-19 Nk cells activating receptors and their therapeutic and diagnostic uses

Publications (1)

Publication Number Publication Date
ATE311464T1 true ATE311464T1 (de) 2005-12-15

Family

ID=11074420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01956747T ATE311464T1 (de) 2000-07-20 2001-07-19 Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen

Country Status (9)

Country Link
US (1) US20040072256A1 (de)
EP (1) EP1301605B1 (de)
JP (1) JP2004504065A (de)
AT (1) ATE311464T1 (de)
AU (2) AU7866201A (de)
CA (1) CA2416733A1 (de)
DE (1) DE60115452D1 (de)
IL (1) IL137419A0 (de)
WO (1) WO2002008287A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002361728A1 (en) * 2001-12-14 2003-06-30 President And Fellows Of Harvard College Immunocellular receptors related to neurological disorders
CA2503748A1 (en) * 2002-11-08 2004-05-27 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
EP1581809A4 (de) * 2002-12-09 2008-11-12 Natspears Ltd Nk-zellrezeptor-konjugate zur behandlung von malignomen
EP1445614A1 (de) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verfahren zur in vitro Überwachung der Entwicklung von HIV Virus eines Individuums
WO2005076001A2 (en) * 2004-02-06 2005-08-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
GB0305478D0 (en) 2003-03-10 2003-04-16 Bioxell Spa Diagnostic and prognostic compounds and method
WO2005000086A2 (en) 2003-06-30 2005-01-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem FRAGMENTS OF NKp44 AND NKp46 FOR TARGETING VIRAL-INFECTED AND TUMOR CELLS
US20070280938A1 (en) * 2003-11-25 2007-12-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Peptides Derived from Natural Cytotoxicity Receptors and Methods of Use Thereof
WO2006103569A2 (en) * 2005-03-18 2006-10-05 Innate Pharma Expression vectors and methods for obtaining nk cell specific expression
JP5368301B2 (ja) 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス 可溶性ヘテロ二量体レセプター及びその使用
US20090182127A1 (en) * 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US9593376B2 (en) 2008-06-02 2017-03-14 Institut Gustave Roussy Natural killer p30 (NKp30) dysfunction and the biological applications thereof
WO2010106542A2 (en) * 2009-03-19 2010-09-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. USE OF NKp46 FOR PREVENTING DIABETES
WO2012175613A1 (en) 2011-06-21 2012-12-27 Innate Pharma NKp46-MEDIATED NK CELL TUNING
EP3211002B1 (de) 2012-03-21 2020-05-13 Ben-Gurion University of The Negev Npk44 ectodomäne abgeleitete peptide
US10363298B2 (en) 2014-01-24 2019-07-30 University Court Of The University Of St. Andrews Immunomodulatory compounds
AU2017238172B2 (en) * 2016-03-21 2024-06-27 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018011803A1 (en) 2016-07-11 2018-01-18 The National Institute for Biotechnology in the Negev Ltd. Fusion proteins with extended serum half life
GB201616006D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Cell modulation
GB201616007D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Novel Adjuvants
GB201616009D0 (en) 2016-09-20 2016-11-02 Univ Court Of The Univ Of St Andrews The Treatment and/or prevention of sepsis
KR20230154235A (ko) * 2021-03-05 2023-11-07 상하이 치루 파마슈티컬 리서치 앤 디벨롭먼트 센터 리미티드 NKp46에 대한 항체 및 이의 적용
CN117304342B (zh) * 2023-09-28 2024-07-19 上海恩凯细胞技术有限公司 嵌合抗原受体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5641875A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania DNA encoding chimeric IgG Fc receptor
AU708339B2 (en) * 1995-02-24 1999-08-05 General Hospital Corporation, The Redirection of cellular immunity by receptor chimeras
MX9708529A (es) * 1995-05-16 1998-02-28 Bristol Myers Squibb Co Herregulinas recombinantes y sus funciones biologicas sobre la activacion del receptor.
EP1029049A2 (de) * 1997-11-07 2000-08-23 Biogen, Inc. Bmog, ein mitglied der myelin-oligodendrocyte glycoprotein familie and seine verwendung

Also Published As

Publication number Publication date
WO2002008287A3 (en) 2002-12-19
EP1301605B1 (de) 2005-11-30
US20040072256A1 (en) 2004-04-15
AU7866201A (en) 2002-02-05
AU2001278662B2 (en) 2006-09-28
JP2004504065A (ja) 2004-02-12
EP1301605A2 (de) 2003-04-16
WO2002008287A2 (en) 2002-01-31
DE60115452D1 (de) 2006-01-05
CA2416733A1 (en) 2002-01-31
IL137419A0 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
ATE311464T1 (de) Nk zellen-aktivierende rezeptoren und deren therapeutische und diagnostische verwendungen
CY1111193T1 (el) Ανθρωπινα cdr-μοσχευμενα αντισωματα και θραυσματα αντισωματων τους
ES2562651T3 (es) Lixisenatida para el uso en el tratamiento de la estenosis o/y la obstrucción del sistema de conductos pancreáticos
DE602005026789D1 (de) Le
BR112016012795A2 (pt) Métodos para a determinação da eficácia do fármaco para o tratamento de linfoma difuso de grandes células b, mieloma múltiplo e cânceres mieloides
UY29504A1 (es) Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
CY1115212T1 (el) Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44
BRPI0821110B8 (pt) anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
NO20054078D0 (no) Humane antistoffer spesifikke for Interleukin 15 (IL15).
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
AR055223A1 (es) Caracterizacion y compensacion de electrodos del ecg
DE60032486D1 (de) Prion protein peptide und deren verwendung
RU94045826A (ru) Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i
NO20024932D0 (no) Kontrastmiddel
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
RU2008104420A (ru) Антитела против рецептора ccr7 для лечения рака
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
TW200637875A (en) Cytotoxicity mediation of cells evidencing surface expression of CD63
GB2449044A (en) Cytotoxicity mediation of cells evidencing surface expression of cd63
HUP0301812A2 (hu) Átvizsgálási (screening) eljárás
ATE466595T1 (de) Verbindungen und methoden für das downregulating der effekte von tgf-beta
ATE449847T1 (de) Hepatitis c rezeptorprotein cd81
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties